Skip to main content

Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control

2008-11-12

Background: Injection of long-acting insulin at bedtime is a common therapeutic approach for patients with type 2 diabetes that is poorly controlled with oral regimens. Neutral protamine lispro (NPL) insulin has demonstrated better glycemic control and similar incidence of hypoglycemic events than that of neutral protamine Hagedorn insulin.


Other Awareness Article

Spiriva Helps COPD Patients Breathe Better

2008-11-19

 People with chronic obstructive pulmonary disease (COPD) breathe better when they add Spiriva to their other respiratory medications, a four-year study shows.


Other Awareness Article

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

2008-11-19

Objective To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.

 


Other Awareness Article

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy

2008-11-26

Background Recent meta-analyses have raised the possibility that rosiglitazone maleate may increase the risk of ischemic cardiovascular events, whereas pioglitazone hydrochloride could not be linked to such a risk .


Other Awareness Article

في علاج عدوى السل الكامنة ((latent TB : استخدام الريفامبين rifampin)) لمدة أربعة أشهر أقل أعراض جانبية من

2008-11-26

دراسة عشوائية تمت نتيجة لما في استخدام دواء ايزونيازايد لمدة تسعة أشهر من عدم انتظام المريض للدواء أو المتابعة والمراقبة للاّثار الجانية خصوصا سمية الكبد ، لذا نحتاج لنظام علاجي اقصر واّمن .

هدفت الدراسة إلى المقارنة بين نوعين من نظم العلاج لعدوى السل إما استخدام استخدام دواء الريفامبين لمدة أربعة أشهر أو استخدام دواء ايزونيازايد لمدة تسعة أشهر .


Other Awareness Article

update of Safety Review Follow-up to the October 1, 2007

2008-11-29

Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa)


This information reflects FDA’s current analysis of available data concerning these drugs.


Other Awareness Article

Ginkgo biloba for Prevention of Dementia

2008-12-01

Context Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G biloba on dementia incidence are lacking.

Objective To determine effectiveness of G biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI).


Other Awareness Article

Peginterferon-induced depression is reversible

2008-12-02

- Depression related to peginterferon therapy for chronic hepatitis C increases with duration of use, but reverses following treatment cessation, according to members of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial.


Other Awareness Article

Statin drugs and amyotrophic lateral sclerosis (ALS)

2008-12-02

An FDA analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as "Lou Gehrig's Disease." The FDA analysis, undertaken after the agency received a higher than expected number of reports of ALS in patients on statins, is based on data from 41 long-term controlled clinical trials. The results showed no increased incidence of the disease in patients treated with a statin compared with placebo.


Other Awareness Article

Vitamin E won't prevent rheumatoid arthritis: study

2008-12-16

Taking vitamin E supplements does not reduce a woman's risk of rheumatoid arthritis (RA), an analysis of data from the Women's Health Study indicates.

"Despite plausible biologic mechanisms," the present randomized, controlled trial does not show that long-term use of vitamin E supplements significantly decreases the risk of developing RA, Dr. Elizabeth W. Karlson and co-researchers conclude.


Other Awareness Article

Subscribe to General health